Ischemic Stroke in COVID-19: A Systematic Review
Ganna Trepet *
Department of Neurology, Deputy Dean of Medical Faculty No. 2, MD in Neurology, Bogomolets National Medical University, 01601, Ukraine, Kyiv, Taras Shevchenko Blvd, 13, Ukraine.
Nataliia Radzikhovska
Department of Neurology, Bogomolets National Medical University, 01601, Kyiv, Taras Shevchenko Boulevard, 13, Ukraine.
*Author to whom correspondence should be addressed.
Abstract
Aims: To determine an association between inflammatory and coagulation markers in a COVID-19 patient with ischemic stroke.
Study Design: We performed a systematic review of 4 databases using the keywords “ischemic”, “stroke”, “COVID-19”,” Virus”
Place and Duration of Study: December 2021 - January 2022.
Methodology: Randomised control trials, observational studies, and systematic reviews were evaluated to ascertain the correlation between inflammatory and coagulation markers in COVID-19 patients with Ischemic stroke. Searches were conducted using Cochrane/EMBASE, PubMed/Medline, and PEDro between (2020-2021).
Results: Of the inflammatory markers, white blood cells (WBC) and platelets did not vary considerably outside their normal ranges. All markers of hypercoagulability were elevated, but only Prothrombin Time corresponded with C-reactive protein (CRP).
Conclusion: Inflammatory markers were not useful in forecasting the development of acute ischemic stroke, but CRP levels may be a possible marker to further research. D-dimer is a tried and true lab test that should be part of management guidelines in the ongoing COVID pandemic.
Keywords: Ischemic stroke, COVID-19 pandemic, C-reactive protein, hypercoagulability